08/29/2024, 01:01 PM UTC
安进公司的GLP-1上涨潜力未被定价Amgen's GLP-1 Upside Is Not Priced In
1、安进公司的股票目前以16.6倍明年盈利合理估值，得益于强劲的现有收入增长和多元化的产品组合。2、新产品如Blincyto、Tezspire和Tepezza正在推动显著的收入增长，验证了近期股价上涨的合理性。3、MariTide，安进的GLP-1候选药物，因其长效作用和较少给药频率，有可能解决当前市场短缺问题，带来潜在上涨空间。1. Amgen's stock is currently fairly valued at 16.6x next year's earnings, supported by strong existing revenue growth and a diversified product portfolio. 2. New products like Blincyto, Tezspire, and Tepezza are driving significant revenue growth, validating recent share price appreciation. 3. MariTide, Amgen's GLP-1 candidate, offers potential upside due to its long-lasting effects and less frequent dosing, potentially addressing current market shortages.
---
本文由大语言模型（LLM）生成，旨在为读者提供半导体新闻内容的知识扩展（Beta）。
